AIMS: The trace amine-associated receptor (Taar) family displays high species- and subtype-specific pharmacology. Several trace amines such as β-phenylethylamine (β-PEA), p-tyramine and tryptamine are agonists at TA(1) but poorly activate rat and mouse Taar4. PRINCIPAL RESULTS: Using rat TA(1) and Taar4 chimera, we identified determinants in transmembrane helices 3 and 6, which, when replaced by the corresponding portion of rat TA(1) , can rescue cell surface expression of rat Taar4. When expressed at the cell surface, rat Taar4 pharmacology was very similar to that of TA(1) and coupled to the Gα(s) -protein/AC pathway. Our data suggest that binding pockets of Taar for surrogate agonists overlap between paralogs. CONCLUSIONS: This implicates that the repertoire of Taar ensures functional redundancy, tissue- and cell-specific expression and/or different downstream signalling rather than different agonist specificity.
AIMS: The trace amine-associated receptor (Taar) family displays high species- and subtype-specific pharmacology. Several trace amines such as β-phenylethylamine (β-PEA), p-tyramine and tryptamine are agonists at TA(1) but poorly activate rat and mouseTaar4. PRINCIPAL RESULTS: Using rat TA(1) and Taar4 chimera, we identified determinants in transmembrane helices 3 and 6, which, when replaced by the corresponding portion of rat TA(1) , can rescue cell surface expression of ratTaar4. When expressed at the cell surface, ratTaar4 pharmacology was very similar to that of TA(1) and coupled to the Gα(s) -protein/AC pathway. Our data suggest that binding pockets of Taar for surrogate agonists overlap between paralogs. CONCLUSIONS: This implicates that the repertoire of Taar ensures functional redundancy, tissue- and cell-specific expression and/or different downstream signalling rather than different agonist specificity.
Authors: Evi Kostenis; Lene Martini; James Ellis; Maria Waldhoer; Arne Heydorn; Mette M Rosenkilde; Pia K Norregaard; Rasmus Jorgensen; Jennifer L Whistler; Graeme Milligan Journal: J Pharmacol Exp Ther Date: 2004-12-22 Impact factor: 4.030
Authors: Lothar Lindemann; Martin Ebeling; Nicole A Kratochwil; James R Bunzow; David K Grandy; Marius C Hoener Journal: Genomics Date: 2005-03 Impact factor: 5.736
Authors: J R Bunzow; M S Sonders; S Arttamangkul; L M Harrison; G Zhang; D I Quigley; T Darland; K L Suchland; S Pasumamula; J L Kennedy; S B Olson; R E Magenis; S G Amara; D K Grandy Journal: Mol Pharmacol Date: 2001-12 Impact factor: 4.436
Authors: David B Wainscott; Sheila P Little; Tinggui Yin; Yuan Tu; Vincent P Rocco; John X He; David L Nelson Journal: J Pharmacol Exp Ther Date: 2006-10-12 Impact factor: 4.030
Authors: T Schöneberg; A Schulz; H Biebermann; A Grüters; T Grimm; K Hübschmann; G Filler; T Gudermann; G Schultz Journal: Hum Mutat Date: 1998 Impact factor: 4.878
Authors: Anna Peters; Petra Krumbholz; Elisabeth Jäger; Anna Heintz-Buschart; Mehmet Volkan Çakir; Sven Rothemund; Alexander Gaudl; Uta Ceglarek; Torsten Schöneberg; Claudia Stäubert Journal: PLoS Genet Date: 2019-05-23 Impact factor: 5.917